Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
WALB,
Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj…
Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj…
Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj…
Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj…
Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj…
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson
PR Newswire New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
June 5, 2022, CHICAGO /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
June 5, 2022, CHICAGO /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients…
posted on Jun. 05, 2022 at 2:11 pm New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from…
New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study…
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021. The Janssen Pharmaceutical Companies of Johnson
Media Contact: Brian Kenney +1 215-620-0111 Investor Relations: Jessica Moore +1 732-524-2955 U.S.
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J. RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with…
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Published: Dec. 29, 2021 at 8:00 AM EST|Updated: moments ago RARITAN, N.J., Dec.
Published: Dec. 29, 2021 at 7:00 AM CST|Updated: moments ago RARITAN, N.J., Dec.
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 29, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Inc. of Johnson
ATLANTA, Ga., December 13, 2021 – The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
ATLANTA, Ga., December 13, 2021– The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in…
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Phase 1b results of teclistamab in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) also presented at ASH…
ATLANTA, Dec. 13, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse…
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
- Clinical Data from More Than 10 Approved and Investigational Treatments for Solid Tumors and Hematologic Malignancies to be…
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Inc. of Johnson
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson
News Release Media Contacts: Brian Kenney Phone: +1 215-620-0111 Satu Glawe Phone: +49 172-294 6264 Investor Relations…
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of…
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of…
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of…
RARITAN, N.J., June 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
U.S. Milestone Follows European Medicines Agency PRIME Designation for this BCMA Bispecific Antibody for the Treatment of…
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
/PRNewswire/ -- The Janssen Pharmaceutical Inc. of Johnson